32 stories mentioning GILD
Every FINWIRES story that references GILD, newest first.
Daniel Patrick O'Day, Director, Chairman & CEO, on April 28, 2026, sold 10,000 shares in Gilead Sciences (GILD) for $1,291,608. Following the Form 4 filing with the SEC, O'Day has control over a total of 632,567 common shares of the company, with 632,567 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/882095/000163864326000020/xslF345X05/wk-form4_1777499620.xml
Gilead Sciences (GILD) said Wednesday the US Food and Drug Administration accepted its new drug application for an investigational once-daily HIV treatment combining bictegravir and lenacapavir, granting priority review with a target action date of Aug. 27.The application is backed by Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, which showed the regimen maintained virological suppression at 48 weeks and was generally well tolerated in adults with HIV, including those switching from multi-tablet regimens or Biktarvy, the company said.The bictegravir 75-milligram and lenacapavir 50-mg combination remains investigational and has not been approved globally, with its safety and efficacy yet to be fully established, the company said.Price: $128.49, Change: $-0.77, Percent Change: -0.60%
Gilead Sciences (GILD) said Tuesday it completed the acquisition of Arcellx in a deal worth $7.8 billion, which paid target investors $115 in cash along with a $5 contingent value right for each share owned.The contingent payout requires an experimental multiple myeloma therapy to generate at least $6 billion in worldwide net sales through 2029, the company said.The acquisition grants full ownership of the treatment to eliminate future royalty and milestone obligations, Gilead Sciences said.The resulting accounting impact is projected to lower 2026 diluted earnings by approximately $5.57 to $5.67 per share, the company added.Price: $128.82, Change: $+1.07, Percent Change: +0.84%
Gilead Sciences (GILD) has an average rating of overweight and mean price target of $161, according to analysts polled by FactSet.Price: $128.85, Change: $+1.10, Percent Change: +0.86%
Arcus Biosciences (RCUS) said Monday it discontinued its phase 3 STAR-121 study in metastatic non-small cell lung cancer after an Independent Data Monitoring Committee recommended stopping the trial for futility.The study, conducted in collaboration with Gilead Sciences (GILD), evaluated domvanalimab plus zimberelimab and chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment, the company said.The decision followed a pre-planned futility analysis indicating the treatment was unlikely to meet its primary endpoint.Shares of Arcus Biosciences were down 5% in Monday trading.Price: $23.05, Change: $-1.20, Percent Change: -4.95%
Gilead Sciences' (GILD) Yeztugo launch is off to a solid start, though not tracking towards a transformational prospect, RBC Capital Markets said in a Friday note.Yeztugo is a prescription medicine used as HIV-1 pre-exposure prophylaxis to reduce the risk of getting HIV-1.The report said feedback from a mini symposium, key opinion leaders and a payer showed a largely positive experience and improving access while noting challenges in catalyzing overall pre-exposure prophylaxis growth, and early bolus could slow."Overall, Yeztugo launch feels solid early, akin to a better Apretude...but not necessarily the mass-market transformational prophylactic we believe was initially hoped for," the report said.The note added that this is likely reflected in consensus' $7 billion peak sales estimate and in its shares.RBC kept its sector perform rating with a price target of $123.Price: $137.88, Change: $-0.67, Percent Change: -0.48%
Gilead Sciences (GILD) has an average rating of overweight and mean price target of $161, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $138.52, Change: $-1.25, Percent Change: -0.89%
Health care stocks were higher before Friday's opening bell, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.5% and the iShares Biotechnology ETF (IBB) advancing 0.2%.Trevi Therapeutics (TRVI) shares were down more than 6% before market open. The company said late Thursday it priced its public offering of 11.6 million common shares at $13 each for about $150 million in gross proceeds.Gilead Sciences (GILD) said Friday it has received all the regulatory approvals required for its previously announced acquisition of Arcellx. The company's shares were nearly 1% higher.Kura Oncology (KURA) stock rose 8% before market open after the company said that new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib showed "robust" antitumor activity in an ongoing clinical trial of darlifarnib in combination with cabozantinib.
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.3%.In corporate news, Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported Q1 results above market estimates. Its shares fell past 5%.Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.8%.QuidelOrtho (QDEL) shares tumbled 28%. The company said late Wednesday it expects preliminary unaudited revenue of $615 million to $620 million for Q1. Analysts polled by FactSet expect $677.8 million.Hims & Hers Health (HIMS) shares jumped past 12% after a senior US health official signaled plans to ease restrictions on certain peptides.
Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.7%.The iShares Biotechnology ETF (IBB) dropped 1.4%.In corporate news, Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a note. Gilead shares were down 0.9%.
Gilead Sciences (GILD) could beat Q1 consensus estimates, but weaker-than-expected persistence rates for Yeztugo point to a potential risk to long-term peak sales for the HIV pre-exposure prophylaxis drug, RBC Capital Markets said in a Wednesday note.Nine months after Yeztugo's launch, RBC analysts examined third-party prescription trends to assess persistence rates, repeat dosing frequency, and broader pre-exposure prophylaxis market growth and switching dynamics.Taking into account data variability and a likely shifting capture rate, initial persistence for the drug appears to be at or below the 70% figure cited in the firm's recent doctor checks, the analysts said.Gilead's core HIV business will continue to provide a solid foundation for the stock's valuation, according to the note.The analysts said they expect continued declines in the company's hepatitis C business, but sustainable patient volumes should still contribute more than $12 billion in cash flows over the next decade.RBC maintained its sector perform rating on the stock and its price target of $123.Price: $138.51, Change: $-1.26, Percent Change: -0.90%
Gilead Sciences (GILD) has an average rating of overweight and mean price target of $160.44, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $138.65, Change: $-0.38, Percent Change: -0.27%
Showing 21-32 of 32